PVI
IMDX

Pura Vida Investments’s Insight Molecular Diagnostics IMDX Stock Holding History

Pura Vida Investments’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.11M Hold
947,134
– – 20.88% 1
2025
Q4 		$7.1M Hold
947,134
– – 26.55% 2
2025
Q3 		$3.14M Buy
947,134
+928,434
+4,965% +$2.62M 19.16% 2
2025
Q2 		$2.86M Sell
18,700
-928,434
-98% -$2.81M 17.2% 2
2025
Q1 		$2.9M Buy
947,134
+292,683
+45% +$791K 21.17% 2
2024
Q4 		$1.56M Buy
654,451
+159,106
+32% +$432K 4.93% 10
2024
Q3 		$1.41M Hold
495,345
– – 0.92% 30
2024
Q2 		$1.46M Sell
495,345
-28,583
-5% -$78.6K 0.92% 32
2024
Q1 		$1.54M Sell
523,928
-63,002
-11% -$195K 0.26% 38
2023
Q4 		$1.47M Sell
586,930
-71,191
-11% -$219K 0.22% 39
2023
Q3 		$2.05M Sell
658,121
-23,130
-3% -$86.1K 0.39% 59
2023
Q2 		$3.13M Sell
681,251
-27,057
-4% -$136K 0.42% 51
2023
Q1 		$5.02M Sell
708,308
-194,506
-22% -$1.44M 0.51% 48
2022
Q4 		$5.79M Hold
902,814
– – 0.3% 81
2022
Q3 		$13.2M Hold
902,814
– – 0.76% 35
2022
Q2 		$16.2M Buy
902,814
+291,616
+48% +$6.63M 0.94% 25
2022
Q1 		$18.2M Hold
611,198
– – 0.59% 40
2021
Q4 		$26.5M Hold
611,198
– – 0.96% 24
2021
Q3 		$43.5M Hold
611,198
– – 1.32% 12
2021
Q2 		$70.2M Hold
611,198
– – 2.18% 6
2021
Q1 		$63.4M Buy
611,198
+297,057
+95% +$28.2M 1.81% 9
2020
Q4 		$15M Buy
314,141
+13,014
+4% +$477K 0.55% 46
2020
Q3 		$8.37M Buy
301,127
+1,941
+0.6% +$55.7K 0.43% 47
2020
Q2 		$11.4M Buy
299,186
+20,272
+7% +$1.05M 1.1% 23
2020
Q1 		$13.7M Sell
278,914
-5,915
-2% -$290K 1.62% 18
2019
Q4 		$12.8M Buy
+284,829
New +$10.3M 1.13% 30

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
FOR
Family Office Research Bethesda, Maryland $230M AUM 23.5% 1-Year Est. Return

Pura Vida Investments's IMDX Position: Q1 2026 in Review

Pura Vida Investments held its Insight Molecular Diagnostics (IMDX) position steady in Q1 2026 at 947,134 shares worth $3.11M. The position accounts for 20.88% of the portfolio, ranked #1.

Pura Vida Investments first reported a position in IMDX in Q4 2019 and has held it in 26 quarters since. The position peaked at $70.2M in Q2 2021. 41 funds tracked by Wall St. Rank hold IMDX as of Q1 2026.

  • Pura Vida Investments held 947,134 shares of Insight Molecular Diagnostics worth $3.11M as of Q1 2026.
  • Pura Vida Investments left its Insight Molecular Diagnostics share count unchanged in Q1 2026.
  • Insight Molecular Diagnostics made up 20.88% of Pura Vida Investments's portfolio in Q1 2026, its #1 holding.
  • Pura Vida Investments first reported a position in Insight Molecular Diagnostics in Q4 2019 and has held it in 26 quarters since.
  • Pura Vida Investments's Insight Molecular Diagnostics position peaked at $70.2M in Q2 2021.
  • 41 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2026.

Based on Pura Vida Investments's 13F filing for Q1 2026, filed 12 May 2026.